Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Oct 25, 2019

SELL
$2.07 - $4.88 $1,078 - $2,542
-521 Closed
0 $0
Q2 2019

Jul 24, 2019

BUY
$2.7 - $4.96 $1,406 - $2,584
521 New
521 $2,000

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $116M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track Fny Investment Advisers, LLC Portfolio

Follow Fny Investment Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fny Investment Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fny Investment Advisers, LLC with notifications on news.